First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting

Afatinib is an ErbB family blocker that is approved for the treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pivotal randomized clinical studies demonstrated that afatinib significantly prolonged progression-free survival compared with platin...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Keunchil, Wan-Teck Lim, Darren, Okamoto, Isamu, Yang, James Chih-Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466470/
https://www.ncbi.nlm.nih.gov/pubmed/31019567
http://dx.doi.org/10.1177/1758835919836374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466470/
https://www.ncbi.nlm.nih.gov/pubmed/31019567
http://dx.doi.org/10.1177/1758835919836374

Ejemplares similares